By Rishika Sadam HYDERABAD (Reuters) -Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly ...

The initiative will provide practical insights into understanding of obesity pathophysiology and its management.

Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

Demand for weight-loss drugs is rising at a fast clip in India where rivals Eli Lilly and Novo Nordisk are competing for ...

Eli Lilly Says India Response to Obesity Drug Mounjaro Is 'Positive', ... Mounjaro has sold more than 81,570 units in India, totalling about 239.4 million rupees ($2.76 million) ...

(Reuters) -Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 billion in global sales since its initial U.S. launch in 2022.

HYDERABAD (Reuters) -Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to ...

The health sector is witnessing notable developments, including the rising demand for obesity drugs in India as Eli Lilly and ...

(Reuters) -Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on meeting demand for the drug in the world's most populous country.